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Abstract 
The literature describes an increasing presence of bisphosphonate-induced osteonecrosis of the jaws (ONJ), charac-
terized by the exposure for over 8 weeks of necrotic bone in the maxillofacial region, after bisphosphonate therapy, 
in the absence of prior maxillary radiotherapy. The present literature review examines the etiopathogenesis, risk 
factors, clinical forms, diagnosis, treatment and prevention of bisphosphonate-induced ONJ. In addition, a review 
is made of all the series involving over 15 patients diagnosed with this disorder between 1 January 2011 and 15 May 
2011. A PubMed-Medline search was carried out with the following key words: “bisphosphonates” and “osteone-
crosis”. The appearance of osteonecrosis is a serious complication, with an increasing incidence, that affects patient 
quality of life and causes important morbidity. All patients treated with bisphosphonates are at risk of developing 
osteonecrosis as a result of such medication. This potential complication therefore should be explained to the pa-
tient by both the prescribing physician and the dental surgeon in charge of oral treatment, with the obtainment of 
informed consent in all cases. 
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Introduction 
Bisphosphonate-induced osteonecrosis of the jaws 
(ONJ) was first described by Marx in the year 2003 (1). 
The disease is characterized by the exposure for over 
8 weeks of necrotic bone in the maxillofacial region, 
after bisphosphonate (BP) therapy, in the absence of 
prior maxillary radiotherapy (2-4). Although the con-
dition is typically confined to the maxillofacial region, 
there have been reports of cases in the hip, tibia and fe-
mur (5). The reason for such exclusive involvement of 
the jaws is subject to controversy. In this sense, many 
factors could be implicated, including the anatomical 
characteristics of alveolar bone, its fine overlying epi-
thelial layer, mechanical stress caused by chewing, in-
flammatory processes (periodontitis), and a complex 
oral microbiota involving the presence of bacteria such 
as Fusobacterium, Bacillus, Actinomyces, Staphylococ-
cus, Streptococcus, Selenomonas and Treponema (6,7). 
Oral bisphosphonates are indicated for the treatment of 
osteopenia, osteoporosis and Paget’s disease (4), while 
intravenous bisphosphonates are used in patients with 
cancer and bone metastases, for the prevention of bone 
complications (pathological fractures, spinal cord com-
pression and problems related to bone irradiation and/
or surgery), and for the treatment of tumor-induced hy-
percalcemia (4,8). The appearance of osteonecrosis is a 
serious complication that affects patient quality of life 
and causes important morbidity (2,9). 
The incidence of ONJ is estimated to be 0.01-0.04% in 
the case of oral BP treatment, versus 0.7-12% in the case 
of intravenous BP administration (4,9) – this percenta-
ge reaching 21% when these drugs are administered for 
three or more years (10). In addition to the administra-
tion route employed, these differences are due to other 
factors such as the treatment indication, potency, admi-
nistered dose and the duration of treatment (11).
The present study reviews the literature on the etiopatho-
genesis, risk factors, clinical forms, diagnosis, treatment 
and prevention of bisphosphonate-induced osteonecro-
sis of the jaws.
Material and methods
A PubMed-Medline search was carried out with the fo-
llowing key words: “bisphosphonates” and “osteone-
crosis”. A total of 382 articles published in the last two 
years were reviewed. Of these, we excluded 31 studies 
in languages other than English and 30 studies in ani-
mals. Apart from these 321 initially considered articles, 
we also included other publications derived from ma-
nual searches and from references in review articles that 
were regarded as important. Study selection was based 
on a review of the titles and abstracts, with a view to ob-
taining the full texts of those publications considered to 
be of relevance in terms of the quality of their methodo-
logical design. The articles obtained from the search 
were classified as corresponding to the following areas: 
etiopathogenesis, risk factors, clinical forms and histolo-
gy, diagnosis and treatment, and prevention. In addition, 
Table 1 includes all the series involving over 15 patients 
diagnosed with bisphosphonate-induced ONJ between 1 
January 2011 and 15 May 2011. 
Article/Year No. 
patients
Disease Mean  
age 
(years)
Sex 
(F/M)
Drug Dura-
tion 
(months)
Antecedents Location 
(Max/Md)
Pautke et al. 
2011 (12)
15 11Ca, 4MM 63.2 10F/5M 10Z, 2I, 1P + Z, 2Z + I 44.72 NA 3 Max/10 Md, 
2Max and Md
Ferlito et al. 
2011 (13)
43 28MM, 15Ca 56.4 NA 43Z 16.2 43EX NA
Wutzl et al. 
2011 (14)
41 20MM, 15Ca, 
5O, 1HX
68.3 25F/16M 25Z, 7P, 1A, 5Z + P, 2Z 
+ I, 1Z + R
6.1 NA 11 Max/26 Md, 
4 Max and Md
Hoefert and 
Eufinger 2011 
(7)
46 10MM, 36Ca 66.1 35F/11M 18Z, 5P, 5I, 8P + Z, 3Z 
+ I, 3Cl + Z, 3P + I, 
1A + Z
11.5 33EX, 3NA, 
7PU, 1AB, 1PI 
and 1SP
9 Max/26 Md, 
6 Max and Md
Manfredi et al. 
2011 (9)
25 25O 68.2 NA 12A, 2Cl, 1I, 1N, 3Z, 
2A + Cl, 3A + I, 2A + R
14.9 15EX, 3I, 7NA 9 Max/16 Md
Maurer et al. 
2011 (15)
21 10Ca, 8MM, 3O 69 16F/5M 15Z, 3I, 3A 47.4 12SP, 9DT 21 Max
Scoletta et al. 
2011 (16)
65 40Ca, 21MM, 
2O, 1RA, 1PD
64.8 45F/20M 57Z, 2P, 5Z + P 13 NA NA
(F/M) = (females/males); (Max/Md) = (upper maxilla/mandible); O = Osteoporosis; Ca = Cancer; MM = Multiple myeloma; RA = Rheumatoid 
arthritis; PD = Paget’s disease; SP = Spontaneous; EX = Extraction; NA = Not available; PU = Pressure ulcer; HX = Histiocytosis X; AB = 
Abscess; PI = Peri-implantitis; DT = Dental treatment. Z = Zolendronate; A = Alendronate; I = Ibandronate; N = Neridronate; P = Pamidronate. 
Cl = Clodronate
Table 1. Bisphosphonate-induced osteonecrosis of the jaws in published series involving more than 15 patients.
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trated in patients with BP-induced ONJ, it is not clear 
whether infection is a primary or a secondary cause of 
the disorder (2,10).
Many patients present antecedents of local trauma, parti-
cularly dental extractions (70%), with a lesser incidence 
of other surgical procedures. ONJ has been reported to 
develop spontaneously in 30-50% of the cases (8, 22), 
particularly in locations where the gingival mucosa is 
thinner (2,10). 
In a review of 468 dental implants in 115 patients sub-
jected to oral BP therapy, no cases of ONJ were obser-
ved, and only two implants failed. The success rate was 
therefore similar to that recorded in patients without BP 
treatment. In the absence of other diseases or medica-
tions, the placement of implants and their osteointegra-
tion during the first three years of treatment with oral 
bisphosphonates can be regarded as safe (23). In another 
retrospective study (24) involving implant placement in 
61 patients treated with oral bisphosphonates for an ave-
rage of 3.3 years, no cases of ONJ were recorded during 
follow-up (12-24 months), and the implant success rate 
was 100%. Nevertheless, it must be taken into account 
that a number of authors (7, 9, 11, 22, 25) have descri-
bed cases of BP-induced ONJ in patients with dental 
implants.
Risk factors
A number of studies (2-4, 14, 26) have analyzed the risk 
factors underlying of BP-induced ONJ. Treatment with 
potent intravenous bisphosphonates such as zolendrona-
te or pamidronate, and tooth extractions, are the most 
important factors, with an estimated risk of between 
6.7% and 9.1% after extraction (4). Other potentially in-
fluencing factors are periodontal or periapical surgical 
procedures, the presence of dental abscesses, anatomical 
factors such as the presence of a torus, the duration of 
BP treatment, the number of treatment cycles, diabetes, 
deficient oral hygiene and the concomitant administra-
tion of corticosteroids or thalidomide (2, 6, 17, 27). A 
genetic influence has also been postulated in the deve-
lopment of the disease through the cytochrome P450-2C 
enzyme system (CYP2C8), since the latter is implicated 
Etiopathogenesis
The molecular structure of the bisphosphonates is simi-
lar to that of the pyrophosphates, with the exception that 
the former have a P-C-P bond at the center of the struc-
ture (3). Bisphosphonates inhibit the enzyme 3-hydroxy-
3-methylglutaryl coenzyme A reductase. Once bound 
to bone, they prevent bone resorption mediated by os-
teoclasts, and stimulate apoptosis of these cells. Bisphos-
phonates have also been reported to exert an antiangio-
genic effect through the suppression of serum interleukin 
levels generated by the endothelial cells (3, 17). A num-
ber of factors have been related to the etiopathogenesis 
of ONJ, such as immune disorders and alterations of the 
reparatory mechanisms, since 95% of all patients with 
ONJ present tumors as background disease. Although 
vascular impairment has been postulated as one of the 
key elements in the etiopathogenesis of ONJ, the latter 
has also been erroneously linked to avascular necrosis in 
other locations such as the hip, since there are no clini-
cal or physiopathological parallelisms between the two 
disorders. Diminished bone turnover and toxicity at both 
bone level and in the soft tissues have also been cited as 
etiopathogenic factors (18). Bisphosphonates have been 
reported to act directly upon keratinocytes and fibro-
blasts, inhibiting their activities through aging processes 
and apoptosis. This in turn affects cell proliferation and 
migration, resulting in a lack of reepithelization of the 
oral mucosa (19). Although the physiopathology of ONJ 
remains to be fully clarified, the inhibition of bone remo-
deling has been suggested to play a significant role. The 
best evidence in support of this hypothesis comes from 
patients not treated with bisphosphonates. There have 
been reports of ONJ in patients treated with drugs such 
as denosumab that inhibit bone remodeling by acting 
upon the RANKL receptor (20). There have also been 
descriptions of ONJ without previous BP treatment in 
patients with herpes-zoster infections and HIV-positive 
individuals (21).
The half-life of the bisphosphonates in blood is short 
(between 30 minutes and 2 hours), though once bound 
to bone these drugs can persist within the body for years 
(1). Although the presence of bacteria has been demons-
STAGING TREATMENT
Stage 1 Exposure of necrotic bone or small oral ulceration without expo-
sure of necrotic bone, with no symptoms.
Daily rinse with 0.12% chlorhexidine and follow-
up.
Stage 2 2a. Exposure of necrotic bone or small oral fistula without 
exposure of necrotic bone, with symptoms controlled by medical 
treatment.
Daily rinse with 0.12% chlorhexidine, antibiotics, 
analgesics and follow-up.
2b. Exposure of necrotic bone or small oral fistula without expo-
sure of necrotic bone, with symptoms not controlled by medical 
treatment.
Daily rinse with 0.12% chlorhexidine, antibiotics, 
analgesics and surgery with elimination of bone 
necrosis.
Stage 3 Mandibular fracture, cutaneous fistula, osteolysis extending to 
lower margin.
Daily rinse with 0.12% chlorhexidine, antibio-
tics, analgesics and extensive surgery with bone 
resection.
Table 2. Proposed staging classification and treatment of bisphosphonate-induced osteonecrosis of the jaws (32).
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in the arachidonic acid metabolism and cholesterol bios-
ynthesis, and can modulate angiogenesis and osteoblast 
differentiation in bone (3, 10).
Clinical forms and histology
Table 2 describes the different potential clinical stages 
of BP-induced ONJ. Patients complain of progressive 
and persistent pain, following an initially asymptomatic 
period. The disorder often produces suppuration through 
gingival fistulas, with posterior exposure of necrotic 
maxillary or mandibular bone through the mucosa. Cli-
nically, these exposed bone areas measure between 0.5-2 
cm in diameter, and several simultaneous exposure si-
tes are frequently observed in one same patient (28). In 
addition, other less common manifestations include loss 
of sensitivity in the territory innervated by the inferior 
alveolar nerve (Vincent’s sign) (10). Regarding the lo-
cation of these areas, mandibular involvement is much 
more common than maxillary bone exposure, and in the 
mandible the molar region is particularly susceptible 
(22) – possibly due to the presence of terminal vascu-
larization (6) that cannot be compensated by peripheral 
perfusion from the gingiva and periodontal tissue.
The histological characteristics in turn comprise osteo-
myelitis with an inflammatory infiltrate of the necrotic 
tissue, while the adjacent zones show the presence of 
Actinomyces and pseudoepitheliomatous hyperplasia 
(15).
Diagnosis and treatment
A number of diagnostic criteria for osteonecrosis of the 
jaws have been proposed (8):
Patients receiving or who have received BP therapy.
The presence of one or more ulcerated lesions affecting 
the mucosa of the alveolar processes, with the exposu-
re of maxillary or mandibular bone. There also may be 
cases without bone exposure, with pain or fistulas, that 
should be subjected to more detailed study.
Exposed bone of necrotic appearance.
Lesions manifesting spontaneously or, more often, after 
dental-alveolar surgery (particularly extractions).
Absence of healing over a period of at least 6 weeks.
Computed tomography (CT) is effective in assessing 
the size and extent of the necrotic bone, and magnetic 
resonance imaging (MRI) can also be used to evalua-
te osteonecrosis, showing diminished signal intensity 
in T1- and T2-weighted sequences. The appearance of 
ONJ on X-rays and in the CT scan is variable and inclu-
des poorly defined areas with a permeated appearance 
showing cortical destruction, bone sequestration, pe-
riosteal reaction or sclerotic changes. The presence of 
sclerosis associated to a disorganized microtrabecular 
structure could represent the first imaging signs of BP-
induced ONJ. The presence of a periosteal reaction and 
bone sequestration in turn is associated to more advan-
ced stage disease (29).
Ruggiero et al. (30) have proposed a clinical classifica-
tion that can be used for staging ONJ and for planning 
treatment. This system includes two new stages with 
respect to the previous classification: the designation 
of “risk category” for those patients treated with oral or 
intravenous bisphosphonates who do not show exposu-
re of necrotic bone; and “stage 0” referred to those pa-
tients who in the absence of clinical evidence of bone 
exposure show nonspecific clinical manifestations such 
as mandibular pain or osteosclerosis (31). A new modi-
fication proposed by Bagán et al. (32), which has been 
supported by other authors (33), is described in Table 3. 
In this classification stage 2 is subdivided according to 
whether the patient remains stable without progression 
or worsening of necrosis or of the signs derived from ne-
crosis (stage 2a), or whether the condition progresses in 
terms of the extent of necrosis or of its derived infectious 
complications, without producing mandibular fracture, 
extraoral fistula or osteolysis (stage 2b). However, in 
contrast to the classification proposed by Ruggiero et al. 
(30) and posteriorly modified by Bagán et al. (32), Woo 
et al. (33) advises subdividing stage 0 according to the 
patient symptoms. Thus, a distinction is made between 
stage 0sa (suspected asymptomatic), corresponding to 
patients without bone exposure but with fistulas or deep 
periodontal pockets causing no symptoms and treated 
only with chlorhexidine rinses; and stage 0ss (suspected 
symptomatic), corresponding to patients without bone 
exposure but with fistulas or deep periodontal pockets 
causing symptoms and treated only with chlorhexidine 
rinses and systemic antibiotics.
The treatment of these patients remains the subject of 
debate. The objective of treatment in patients diagno-
sed with ONJ should be to eliminate the pain, control 
the soft tissue and bone infection, and avoid or reduce 
the progression of bone necrosis. Several authors (22, 
30) consider that the suppression of oral BP treatment 
for a period of 6-12 months results in clinical improve-
Before treatment 
with intravenous 
bisphosphonates
Discard sites of infection and eliminate them before starting bisphosphonate therapy.• 
Extraction of teeth with poor prognosis.• 
During treatment 
with intravenous 
bisphosphonates
Controls every 6 months.• 
Preventive tartrectomy, plaque control and elimination of periodontal pockets.• 
Avoid extractions; if necessary, provide prophylactic antibiotic treatment, 0.12% chlorhexidine rinses; • 
surgery should be as little traumatic as possible, with socket curettage and placing of stitches.
Table 3. General recommendations in patients receiving intravenous bisphosphonate treatment (8).
e64
J Clin Exp Dent. 2012;4(1):e60-5.                                                               Osteonecrosis due to bisphosphonates.
ment and even spontaneous resolution of the condition. 
Suspension is therefore advisable, provided the systemic 
clinical conditions of the patient allow the interruption 
of BP therapy. Since 25% of trabecular bone and 3% 
of cortical bone are renewed each year, the interruption 
of BP treatment theoretically could have a beneficial 
effect, since the newly formed bone is unable to absorb 
BP (14). However, in a study involving 25 patients, BP 
suppression was not seen to exert an effect (9). Corti-
costeroid discontinuation also should be considered in 
patients concomitantly receiving these drugs as main-
tenance therapy (34). It has been suggested that these 
patients should receive conservative management, since 
the mucosal disruptions resolve in at least 23-53% of 
the cases after following a series of recommendations: 
administration of topical chlorhexidine and systemic an-
tibiotics in cases of pain and infection, the suppression 
of BP treatment, or hyperbaric oxygen therapy (17,25). 
A preliminary study (27) of 10 patients has described 
a conservative treatment option based on direct ozone 
(O3) application in gel form, thereby facilitating ozone 
release over the necrotic bone. Beneficial results were 
obtained, since in two patients (20%) the radiological 
controls showed disappearance of the lesions and com-
plete regeneration of the oral tissues. The shedding of 
bone sequestration was recorded in 8 patients (80%), 
with complete reepithelization of the lesions in two ca-
ses. There were no cases of ONJ relapse after 8 months 
of follow-up. Such therapy therefore should be regarded 
as an effective, safe and simple treatment option in appli-
cation to BP-induced ONJ measuring ≤ 2.5 cm in size. 
Another described treatment option is the administration 
of isoprenoid geranyl diphosphate (metabolic form of 
geraniol), which reverts inhibition of the mevalonate pa-
thway induced by nitrogenated bisphosphonates (35).
Bocanegra-Pérez et al. (36) recommend treating these 
patients on a conservative basis, administering oral anti-
biotics such as amoxicillin – clavulanic acid 1000/62.5 
mg two tablets/day/30 days, or metronidazole 250 mg 
two tablets/8 hours/10-20 days, and 0.12% chlorhexi-
dine rinses 3-4 times a day. The fistulas in turn can be 
treated with an intravenous perfusion of ciprofloxacin 2 
mg/ml. In a case series published by Marx et al. (37), 
90% of the patients in stages 1 and 2 were stabilized 
with conservative treatment in the form of oral rinses 
and systemic antibiotics. Another study (25) found 
3-10% of the patients to fail to respond to conservative 
treatment or suffer pathological fractures – surgery be-
ing needed, with resection of the necrotic bone. The im-
portance of aggressive treatment has been underscored 
in a study (38) in which conservative management was 
not effective. A surgical technique has been described, 
based on fluorescence guided bone resection of 20 ONJ 
zones in 15 patients – the success rate being 85% after 
four weeks of follow-up (12). The treatment response 
has been reported to be variable, with a poorer respon-
se in patients with maxillary sinusitis associated to ONJ 
(15). The treatment guidelines proposed by Bagán et al. 
(32) are described in Table 2. 
Prevention
It has long been reported that the determination of CTX 
(C-terminal telopeptide of type 1 collagen) in the serum 
of patients treated with BP could be of use in predic-
ting ONJ in patients subjected to oral surgery. Patients 
with CTX ≥150 pg/ml can undergo any type of surgery 
with only minimum risks and without the need to sus-
pend the medication; however, in the presence of CTX 
< 150 pg/ml the risks increase (22). In contrast, other 
authors (39,40) have not found CTX to offer any true 
predictive capacity. As a result, its use must be viewed 
with caution, and the CTX values cannot be used as a 
definitive indicator of the risk of suffering BP-induced 
ONJ. Serum osteocalcin is another marker that could 
be of use in predicting the risk of ONJ. In this sense, 
concentrations below the normal limits could indicate 
problems with the bone formation process, and may be 
regarded as a risk factor (40). Periapical X-rays can also 
be important, revealing sclerotic areas and loss of the 
inferior alveolar nerve contour caused by progressive 
sclerosis (29).
It has been shown that the adoption of preventive mea-
sures before and during intravenous BP therapy in can-
cer patients with bone metastases and in individuals with 
multiple myeloma is accompanied by a 75% reduction in 
the incidence of ONJ. Whenever possible, such preventi-
ve measures should include adequate oral hygiene before 
administering BP treatment, together with the extraction 
of teeth showing a poor prognosis, caries control, and 
monitorization of the correct fitting of removable den-
tures (2). Table 3 summarizes these recommendations, 
which moreover can be extrapolated to patients treated 
with bisphosphonates via the oral route (8). 
All patients treated with bisphosphonates are at risk of 
developing osteonecrosis as a result of such medication. 
This potential complication therefore should be explai-
ned to the patient by both the prescribing physician and 
the dental surgeon in charge of oral treatment, with the 
obtainment of informed consent in all cases.
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